Pyramid Biosciences Appoints Biren Amin as Chief Financial and Strategy Officer

ALTHAM, Mass.–(BUSINESS WIRE)–Pyramid Biosciences, Inc.., a Boston-based clinical-stage biotechnology company focused on developing new, highly differentiated, precision cancer therapies, today announced the expansion of its management team. Biren Amin, MS, MBA joined the company as Chief Financial and Strategic Officer. Mr. Amin joins Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Officer (CFO).

“We are delighted to have Biren join our leadership team, particularly during this time of significant growth for the company,” said Brian Lestini, MD, Ph.D., CEO of Pyramid Biosciences. “His accomplishments over two decades in oncology and biotechnology, both in the capital markets and in industry, are impeccable and unparalleled. As we strive to serve patients by advancing and expanding our pipeline, Biren’s strategic leadership and expertise will play a critical role in accomplishing our mission.

“I look forward to working with the exceptional team at Pyramid Biosciences as we advance our best-in-class NTRK inhibitor, PBI-200, through clinical development and diversify our pipeline,” said Mr. Amin. “My focus will be to ensure that our corporate strategy and business development activities align with our goal of bringing cutting-edge, experimental oncology therapies to society and to patients.”

Prior to joining Pyramid Biosciences, Mr. Amin served as Chief Financial Officer at Immuneering Corporation, a US-based, oncology-focused preclinical biopharmaceutical company, where he led a successful initial public offering of $120 million. Previously, Mr. Amin spent nearly two decades on Wall Street, where he built a strong track record in small and mid-cap biotechnology companies, focusing on oncology, CNS disorders, ophthalmology and rare diseases. Mr. Amin spent a decade at Jefferies Financial Group as managing director of their equity research group. Meanwhile, Mr. Amin was named Best Stock Picker in Biotechnology in 2013 by the Financial Times. Prior to joining Jefferies, Mr. Amin was an equity research analyst covering biotechnology and pharmaceuticals at several companies, including Prudential Equity Group. He started his career at Aventis Pharmaceuticals (currently part of Sanofi SA) where he held the position of Senior Manager in their Scientific Competitive Intelligence group. Mr. Amin earned his Bachelor of Science (BS) in Pharmacy from the University of Science in Philadelphia, his Master of Science (MS) in Pharmacy from Long Island University, and his Master of Business Administration (MBA) from the Stern School of Business at New York University. He currently sits on the board of the Axiom REACH Foundation.

About Pyramid Biosciences:

Founded in 2015, Pyramid Biosciences is a clinical-stage biotechnology company focused on the development of novel, highly differentiated precision therapies for cancer. Based in Boston, Massachusetts, Pyramid Biosciences is currently in clinical development of two highly selective tropomyosin receptor kinase (TRK) inhibitors. For more information, please visit: www.pyramidbio.com

Comments are closed.